Updates are available Correction dated 2021-03-04

Article History

Received: 23 March 2020

Accepted: 7 December 2020

First Online: 6 January 2021

Change Date: 4 March 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1186/s13075-021-02459-1

Ethics approval and consent to participate

: This study was approved by the University of Michigan Institutional Review Board.

: Not applicable

: DAF has received grant support from Seattle Genetics, Gilead and Regeneron, unrelated to the subject of this study. He has received consultant fees from Pfizer, CSL Behring, and Juno Therapeutics, also unrelated.SKL is currently employed full-time at SystImmune Inc. doing work unrelated to the subject of this study. There are no competing interests.CS has received consultant fees from EICOS Sciences, Inc.SP is on the SAB of Abpro Inc. but this is not related to the subject to this study.DF has received grant support from Actelion, Amgen, BMS Corbus, Galapagos GSK, NIH, Novartis, Pfizer, Sanofi, and Roche/Genentech. He has received consultant fees from Actelion, Amgen, BMS, Corbus, Galapagos Novartis, and Pfizer.Dr. Khanna reports personal consultancy fees as part of clinical trials design from Acceleron, Actelion, Blade Therapeutics, Galapagos, GSK, Mitsubishi Tanabi, Sanofi-Aventis/Genzyme, and UCB Pharma and grants and personal consultancy fees from Bayer, BMS, and Genentech/Roche during the conduct of this study. He has stock options in Eicos Sciences Inc. He is funded by the NIH/ NIAMS K24 AR063120.MLW has received consulting fees from Bristol Myers Squib. Dr. Whitfield is a scientific founder and has received unrelated grant support from Celdara Medical LLC. He has received unrelated consulting fees from Abbvie, Acceleron, Celdara Medical, Corbus Pharmaceuticals, and Boeringer-Ingelheim.PC, SR, RO, AS, EW, VJB—no competing interests.